ALX Oncology Reports Data From ASPEN-06 Phase 2 Trial; Says Evorpacept Combination Achieved Confirmed Overall Response Rate Of 40.3% Compared To 26.6% For Control Arm
Author: Benzinga Newsdesk | July 31, 2024 04:03pm
Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial.
In the pre-specified population of patients with fresh HER2-positive biopsies, evorpacept combination showed the greatest benefit with ORR of 54.8% vs. 23.1% in the control, suggesting HER2-expression strongly correlates with evorpacept efficacy and validating its mechanism of action.
Posted In: ALXO
